Literature DB >> 16195983

Effects of short-term salbutamol ingestion during a Wingate test.

B Le Panse1, K Collomp, H Portier, A-M Lecoq, C Jaffre, H Beaupied, O Richard, L Benhamou, J De Ceaurriz, D Courteix.   

Abstract

The effects of a chronic salbutamol intake (SAL, 12 mg/d during 3 weeks) on changes in body composition, metabolic indices and performance during a 30-second Wingate test were determined in 8 strength-trained male athletes (T) and 7 sedentary male (UT) subjects, according to a double-blind, randomized, cross-over protocol. Blood samples were collected both at rest, at the end of the test, and during passive recovery (5 min, 10 min, 15 min) for leptin (at rest), and blood lactate measurements. No significant changes in lean body mass, fat mass, and leptin were observed with SAL treatment in either group during the trial. Peak power was significantly increased (p < 0.05) after SAL intake in all subjects (T: 11.9 %; UT: 8.3 %) with a decrease in time to peak power with SAL compared to placebo (PLA) (p < 0.05). There was no change in total work performed and in fatigue indices with SAL compared to PLA. Blood lactate was significantly increased after SAL vs. PLA during the recovery (p < 0.05) in all subjects. The data demonstrate that the chronic administration of therapeutic levels of salbutamol increases maximal anaerobic power in man, irrespective of the subjects' training status. This study also rules out any implication of an anabolic effect in this improvement in performance during supramaximal exercise. Further studies are necessary to clarify the mechanisms involved.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16195983     DOI: 10.1055/s-2004-821224

Source DB:  PubMed          Journal:  Int J Sports Med        ISSN: 0172-4622            Impact factor:   3.118


  15 in total

1.  Acute supra-therapeutic oral terbutaline administration has no ergogenic effect in non-asthmatic athletes.

Authors:  Anthony M J Sanchez; Fabio Borrani; Marie Amélie Le Fur; Anais Le Mieux; Virgile Lecoultre; Guillaume Py; Christophe Gernigon; Katia Collomp; Robin Candau
Journal:  Eur J Appl Physiol       Date:  2012-07-06       Impact factor: 3.078

Review 2.  β₂-Agonists and physical performance: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Babette M Pluim; Olivier de Hon; J Bart Staal; Jacqueline Limpens; Harm Kuipers; Shelley E Overbeek; Aeilko H Zwinderman; Rob J P M Scholten
Journal:  Sports Med       Date:  2011-01-01       Impact factor: 11.136

Review 3.  Do inhaled beta(2)-agonists have an ergogenic potential in non-asthmatic competitive athletes?

Authors:  Wilfried Kindermann
Journal:  Sports Med       Date:  2007       Impact factor: 11.136

4.  Beta2-Agonist Doping Control and Optical Isomer Challenges.

Authors:  Glenn A Jacobson; J Paul Fawcett
Journal:  Sports Med       Date:  2016-12       Impact factor: 11.136

Review 5.  An Abductive Inference Approach to Assess the Performance-Enhancing Effects of Drugs Included on the World Anti-Doping Agency Prohibited List.

Authors:  Andreas Breenfeldt Andersen; Glenn A Jacobson; Jacob Bejder; Dino Premilovac; Stephen M Richards; Jon J Rasmussen; Søren Jessen; Morten Hostrup
Journal:  Sports Med       Date:  2021-04-02       Impact factor: 11.136

6.  Short term salbutamol ingestion and supramaximal exercise in healthy women.

Authors:  B Le Panse; A Arlettaz; H Portier; A-M Lecoq; J De Ceaurriz; K Collomp
Journal:  Br J Sports Med       Date:  2006-05-10       Impact factor: 13.800

7.  Effect of acute and short-term oral salbutamol treatments on maximal power output in non-asthmatic athletes.

Authors:  Anthony M J Sanchez; Katia Collomp; Juliette Carra; Fabio Borrani; Olivier Coste; Christian Préfaut; Robin Candau
Journal:  Eur J Appl Physiol       Date:  2012-01-10       Impact factor: 3.078

8.  Effects of acute salbutamol intake during supramaximal exercise in women.

Authors:  Bénédicte Le Panse; Alexandre Arlettaz; Hugues Portier; Anne-Marie Lecoq; Jacques De Ceaurriz; Katia Collomp
Journal:  Br J Sports Med       Date:  2007-01-30       Impact factor: 13.800

9.  Salbutamol intake and substrate oxidation during submaximal exercise.

Authors:  A Arlettaz; B Le Panse; H Portier; A-M Lecoq; R Thomasson; J De Ceaurriz; K Collomp
Journal:  Eur J Appl Physiol       Date:  2008-10-17       Impact factor: 3.078

10.  Salbutamol exhibits androgenic activity in vitro.

Authors:  André O von Bueren; Risheng Ma; Margret Schlumpf; Walter Lichtensteiger
Journal:  Br J Sports Med       Date:  2007-05-17       Impact factor: 13.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.